Zacks Research Issues Negative Outlook for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research reduced their Q2 2025 earnings estimates for Ironwood Pharmaceuticals in a research note issued on Thursday, March 20th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.01 per share for the quarter, down from their previous forecast of $0.04. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.24 EPS and FY2027 earnings at $0.36 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Several other brokerages also recently weighed in on IRWD. JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Finally, Craig Hallum decreased their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $1.50 on Monday. Ironwood Pharmaceuticals has a fifty-two week low of $1.34 and a fifty-two week high of $9.01. The business has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $3.43. The stock has a market capitalization of $240.04 million, a PE ratio of -50.00 and a beta of 0.37.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 192,381 shares of company stock worth $338,591. Insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV increased its position in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $36,000. Journey Strategic Wealth LLC bought a new position in Ironwood Pharmaceuticals during the fourth quarter worth $45,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $47,000. Finally, Xponance Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.